Tuesday, August 4, 2020
News
NEWS HOME
»
PRESS RELEASES

European Commission approves third nintedanib indication in pulmonary fibrosis1
  SocialTwist Tell-a-Friend  
   


Date: 16-07-2020 9:52AM
Source: Boehringer Ingelheim
Category: General, Food & Drink, Govt. & Public Policy, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany

Business Wire India

  • The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1
  • The decision is based on the results of the INBUILD® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2
  • Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in more than 40 countries.



Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6

Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality similar to those with IPF, the most frequent form of idiopathic interstitial pneumonias.8 The course of the disease and the symptoms are similar in progressive forms of chronic fibrosing ILDs regardless of the underlying ILD diagnosis, and as many as 18% to 32% of patients with non-IPF ILDs are estimated to be at risk for developing a progressive fibrosing disease behavior.9,10

The approval is based on the results of INBUILD®, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.2 The primary endpoint was the annual rate of decline in forced vital capacity (FVC) in mL assessed over a 52-week period. Patients on placebo lost 188mL lung volume over a year, while patients on nintedanib lost 81mL. This was measured as adjusted annual rate of decline over 52 weeks and meant that nintedanib slowed the lung function decline by 57% versus placebo.2 The treatment effect of nintedanib in slowing FVC decline compared with placebo seen in INBUILD® was consistent for all patients, regardless of the fibrotic pattern on high-resolution computed tomography (HRCT) and it was also consistent with the results in nintedanib trials studying patients with IPF and SSc-ILD.2,11,12,13

In the trial, nintedanib was associated with numerical reductions in the risk of acute exacerbation or death versus placebo.2 Treatment benefit may also be accompanied by reduced worsening of patient-reported outcomes such as dyspnea and cough.14 In addition, the safety profile observed in INBUILD® was consistent to what has been seen in patients with IPF and SSc-ILD treated with nintedanib previously.2

“Making your voice heard when living with a rare life-threatening condition can be very hard and also frightening, especially if no treatment option is available,” said Liam Galvin, Secretary of the European Idiopathic Pulmonary Fibrosis and Related Disorder Federation (EU-IPFF). “The European Commission’s decision is great news for people who are at risk of developing pulmonary fibrosis due to a progressive ILD. Pulmonary fibrosis causes irreversible decline in lung function and this new indication brings much hope to those affected and their loved ones.”

“We are very pleased with the European Commission’s decision to approve nintedanib as the first treatment in the EU for a group of chronic fibrosing ILDs that are progressing,” added Peter Fang, Senior Vice President and Head of Therapeutic Area Inflammation at Boehringer Ingelheim. “Living with fibrotic diseases greatly impacts the lives of the affected. Various underlying diseases can lead to the development of pulmonary fibrosis and until now, no treatment option was available. Bringing new hope to those patients constitutes a therapeutic breakthrough.”

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/ecapprovalnintedanibildpf



CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Alexander Kurz
55216 Ingelheim/Germany
Tel.: +49 (6132) 77-184531
Mobile: +49 (151) 68948378
Email: press@boehringer-ingelheim.com

More Press Releases

Moody’s Analytics Repeats IFRS 9 Wins at Risk Technology Awards

First Eagle to Open Its First German Office in More Than 80 Years; New Hire Louanges Will Direct International Wholesale Business From Munich

Hengli Petrochemical Announces Start-up of its 5th PTA Line Utilising INVISTA’s P8 PTA Technology

Dole Unveils Integrated Strategy Against Banana Disease

Spykke Innovations Partners with tracesafe, to Launch Unique COVID Safety Wristbands in India

Freedom for Our Girls: Breaking Menstrual Barriers

Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

Craft Silicon and PayU Announce Strategic Association to Advance Digital Loan Repayment Solutions for Lending Institutions

With World’s 1st AI and ML Powered Annual-Recurring-Subscription-Model, Frinza Is All Set to Disrupt the Global Gifting Industry

Crossbeats Brings You Work from Home’s Best Bud in Its Beast of a New True Wireless Earphones

Preferred Equity Offering of Lead Real Estate via a Digital Securities Issuance, Brought to Market by GRIP, Securitize and Rialto

Andersen Global Continues West African Expansion with Addition of Tax and Legal Firm in Benin

New One-Stop Resource Center Gives Developers a Robust Array of Tools to Easily Manage, Monitor and Integrate Limelight Services

India Angel Fund invests in Mental Wellness Startup IPHM Services, round led by Monaliesa Sarkar, Jyoti Tiwari, Koel Dutta, Sabana Khatoon, Dr. Vikaas Grover and Rahul Narvekar

CoinEx $50M Ecosystem Development Fund Points First Investment as OneSwap

Wipro Selected as Strategic Partner by Metro Bank to Drive IT Transformation

Velodyne Lidar Sensors Power Emesent’s Hovermap to Fly Beyond the Visual Line of Sight

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trialin adults with and without diabetes

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

NWFI Says Everyone is Looking at India as an Alternative to China and Allowing Exports Will Boost the Domestic Industry

UL Issues First Safety Mark for Hyperbaric Chambers in India

Abbott and 1mg Bring Continuous Glucose Monitoring Solutions Closer to Indian Homes

Face Mask Killing Covid-19, Tested by US-Based ISO Certified Laboratory, Developed and Launched by an Indian Start-up

Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

Philips Introduces Revolutionary Haircare High-Tech Devices and DIY Female Grooming Products

Taobao Introduces Maker Rating System to Champion Young Entrepreneurs, Originality

Sustainable Mica Policy and Vision Prepared by Responsible Mica Initiative with Jharkhand Government and Civil Society Support

MOGAS Wins Multimillion Dollar Bid to Supply Valves for Southeast Asian Refinery

Bank of Baroda’s Credit Card Arm Readies for Digital Transformation with Implementation of Fiserv Technology

Aspect Announces General Availability of Aspect Unified IP 7.4 SP1, the Premier Enterprise Contact Center Solution for High Volume Customer Outreach

Recipe for Growth: Balancing Health, Indulgence and Taste Key to Drive Biscuit and Cookie Growth in India

Automation Industry Leader, Armstrong Along With Indian Rocket Scientists Launched UWe Safe for Contactless 3D Sanitization

WorldRemit Wishing All Those Celebrating a Blessed Eid al Adha

DNSC Introduces the “Typhoon” C20590 MX, the World’s Lowest Cost 100 ppm Full-Color All-In-One MICR Inkjet System

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Ayodhya stalwarts may stay away from 'bh...
IndiGo pilot killed in car crash in Hyde...
Kerala: Suspected 'mentally deranged' ma...
Manipur CM innaugurates 300-bedded COVID...
'Conspirators behind Mujib killing, Hasi...
Curfew ordered in Srinagar on August 4 a...
More...    
 
 Top Stories
B'desh underwater tunnel project 'c... 
1,009 new cases take Gujarat's Covi... 
IndiGo pilot killed in car crash in... 
With 89 fresh COVID-19 cases, Indor... 
Indian envoy in Afghanistan meets A... 
Yediyurappa doing well, clinically ... 
Kerala: Suspected 'mentally derange... 
Assam situation limps towards norma...